QSV Biologics, Ltd. and Helix Biopharma Corporation Sign Letter of Intent in Process Development and Manufacture of L-DOS47 Lung Cancer Therapeutic
December 19, 2005
19 December 2005
(Aurora, Ontario) – Helix BioPharma Corp. (Helix; TSX, FSE: “HBP”) today announced that it has signed an agreement with Edmonton, Alberta-based QSV Biologics (QSV) to develop the cGMP manufacturing process for L-DOS47.
“The signing of this agreement with QSV is a major step in the L-DOS47 program,” said Dr. Donald Segal, President and CEO of Helix. “We believe QSV’s high caliber personnel and facilities for biopharmaceutical manufacturing will accelerate the cGMP production of L-DOS47 for our upcoming preclinical and human clinical studies.”
Dr. Graeme Macaloney, QSV President & CEO said: “Helix is one of a select few biotech firms whose experienced management team has successfully taken products to market. The combination of a top class management team and the potential of L-DOS47 is expected to make Helix an excellent client and partner for QSV”.
About L-DOS47
L-DOS47 combines Helix’s proprietary DOS47 new drug candidate with a highly specific antibody, to form a potential new targeted drug product for the treatment of adenocarcinoma of the lung, the most common form of cancer in the world today. L-DOS47 is thought to function by leveraging a natural process in the body called the urea cycle, to produce an anti-cancer effect. It is based upon a naturally occurring enzyme called urease that essentially reverses the urea cycle by breaking down urea into metabolites that include ammonia and hydroxyl ions. By doing so at the site of cancerous tissues in the body, L-DOS47 is believed to modify the microenvironmental conditions of lung cancer cells in a manner that leads to their death. Among these theorized effects, L-DOS47 is believed to stimulate an increase in the pH of the microenvironment surrounding the cancerous cells, effectively reversing the acidic extra-cellular conditions that are known to be necessary for cancer cell survival. As well, the local production of ammonia at the site of cancerous tissues is thought to readily diffuse into the cancer cells to exert a potent cytotoxic effect by interfering with their critical metabolic functions.
About QSV Biologics Ltd.
QSV is a privately held contract manufacturing organization (CMO), highly specialized in the cGMP manufacturing of biopharmaceuticals. As a dedicated contract manufacturer, QSV offers cell bank development, process & analytical development, technology transfer, scale up and pre-clinical through Phase III & early commercial manufacturing. QSV is the sole CMO recipient of the Frost & Sullivan 2005 best practices award for Customer Value Enhancement. More information can be obtained from www.qsvbiologics.com.
About Helix BioPharma Corp.
Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The Company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix’s product development initiatives include its Topical Interferon Alpha-2b and its novel L-DOS47 new drug candidate. Helix is listed on the TSX under the symbol “HBP”, and quoted on the Frankfurt, Berlin, Munich and Stuttgart Stock Exchanges under the same symbol.
For further information please contact Mr. Richard Hetrick, Manager of Business Development, QSV Biologics at 484-678-4820.
